Al-Harbi K et al. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence 2012; 6: 369-388.
Rush AJ1, Trivedi MH, Wisniewski et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163(11): 1905‒1917.
World Health Organisation. Depression and Other Common Mental Health Disorders: Global Health Estimates, 2017. Available from:
https://bit.ly/2Gzn8CJ (link is external). Last accessed September 2018.
World Federation for Mental Health. DEPRESSION: A Global Crisis, 2012. Available from:
https://bit.ly/1SX2x6J (link is external). Last accessed September 2018.
World Health Organisation. Depression Fact Sheet, 2018. Available from
http://www.who.int/news-room/fact-sheets/detail/depression (link is external). Last accessed September 2018.
Diagnostics and statistical manual of mental disorders. Fifth Edition. 2013.
APA. Practice guidelines for the treatment of patients with major depressive disorder. Third edition, 2010.
Lepine JP, Briley M. The increasing burden of depression.Neuropsychiatr Dis Treat 2011; 7(Suppl 1): 3-7.
Ferrari AJ, Charlson FJ, Norman RE et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10(11): e1001547.
Sobocki P, Jönsson B, Angst J et al. Cost of depression in Europe. J Ment Health Policy Econ 2006; 9(2): 87-98.
Anacker C. New Insight Into the Mechanisms of Fast-Acting Antidepressants: What We Learn From Scopolamine. Biol Psychiatry 2018; 83(1): e5-e7.
Leuchter AF, Cook IA, Hunter AM et al. A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci 2009; 11(4): 435–446.
Munoz C. recovering usual functioning in depressed patients. Medicographia 2014; 36(4): 501-507.
Machado-Vieira R, Baumann J, Wheeler-Castillo C et al. The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. Pharmaceuticals 2010; 3(1): 19-41.
Machado-Vieira R, Salvadore G, Luckenbaugh DA et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008; 69(6): 946-958.
Oluboka OJ, Katzman MA, Habert J et al. Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. Int J Neuropsychopharmacol 2017; 21(2): 128-144.
Gormley N1, O'Leary D, Costello F et al. First admissions for depression: is the 'no-treatment interval' a critical predictor of time to remission?. J Affect Disord 1999; 54(1-2): 49-54.
Okuda A, Suzuki T, Kishi T et al. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci 2010; 64(3): 268-273.
Bukh JD, Bock C, Vinberg M et al. The effect of prolonged duration of untreated depression on antidepressant treatment outcome. J Affect Disord 2013; 145(1): 42-48.
Reid I, Cameron I, MacGillivray S et al. Depression: current approaches to assessment and treatment. Prescriber 2014; 25(4): 16-20.
van Krugten FC, Kaddouri M, Goorden M et al. Indicators of patients with major depressive disorder in need of highly specialized care: A systematic review. PLOS One 2017; 12(2): e0171659.